BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen K, Shang Z, Dai AL, Dai PL. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. Life Sci 2020;255:117816. [PMID: 32454155 DOI: 10.1016/j.lfs.2020.117816] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Altıntop MD, Akalın Çiftçi G, Yılmaz Savaş N, Ertorun İ, Can B, Sever B, Temel HE, Alataş Ö, Özdemir A. Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action. Int J Mol Sci 2023;24. [PMID: 36768971 DOI: 10.3390/ijms24032648] [Reference Citation Analysis]
2 Yakovlev VA, Sullivan SA, Fields EC, Temkin SM. PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. Front Oncol 2023;13:1124147. [PMID: 36910637 DOI: 10.3389/fonc.2023.1124147] [Reference Citation Analysis]
3 Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G. Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer. European Journal of Medicinal Chemistry 2022;244:114851. [DOI: 10.1016/j.ejmech.2022.114851] [Reference Citation Analysis]
4 Innets B, Thongsom S, Petsri K, Racha S, Yokoya M, Moriue S, Chaotham C, Chanvorachote P. Akt/mTOR Targeting Activity of Resveratrol Derivatives in Non-Small Lung Cancer. Molecules 2022;27. [PMID: 36500361 DOI: 10.3390/molecules27238268] [Reference Citation Analysis]
5 Ouyang X, Shi X, Huang N, Yang Y, Zhao W, Guo W, Huang Y. WDR72 Enhances the Stemness of Lung Cancer Cells by Activating the AKT/HIF-1α Signaling Pathway. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/5059588] [Reference Citation Analysis]
6 Gong C, Li W, Wu J, Li YY, Ma Y, Tang LW. AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis. J Radiat Res 2023;64:33-43. [PMID: 36300343 DOI: 10.1093/jrr/rrac064] [Reference Citation Analysis]
7 Song L, Liu S, Zhao S. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. Bioengineered 2022;13:11240-57. [PMID: 35485300 DOI: 10.1080/21655979.2022.2064205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang D, Ao J, Xiong Y, Zhang X, Zhang W. Systematic Analysis of Stress Granule Regulators-Associated Molecular Subtypes Predicts Drug Response, Immune Response, and Prognosis in Non-Small Cell Lung Cancer. Front Cell Dev Biol 2022;10:868918. [DOI: 10.3389/fcell.2022.868918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang P, Hu Y, Qu P, Zhao Y, Liu J, Zhao J, Kong B. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway. Bioengineered 2022;13:1931-41. [PMID: 35001804 DOI: 10.1080/21655979.2021.2022268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu Z, Jia M, Zhao W, Huang X, Yang X, Chen D, Qiaolongbatu X, Li X, Wu J, Qian F, Lou Y, Fan G. Schisandrol A, the main active ingredient of Schisandrae Chinensis Fructus, inhibits pulmonary fibrosis through suppression of the TGF-β signaling pathway as revealed by UPLC-Q-TOF/MS, network pharmacology and experimental verification. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wang M, Tang W, Gong N, Liu P. Sodium Danshensu inhibits the progression of lung cancer by regulating PI3K/Akt signaling pathway. Drug Dev Res 2021. [PMID: 34196024 DOI: 10.1002/ddr.21846] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 2021:S1044-579X(21)00188-7. [PMID: 34175443 DOI: 10.1016/j.semcancer.2021.06.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
13 Zhang F, Meng J, Jiang H, Feng X, Wei D, Meng W. GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling. Anal Cell Pathol (Amst) 2021;2021:5589532. [PMID: 34007784 DOI: 10.1155/2021/5589532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Front Pharmacol 2021;12:628690. [PMID: 33790792 DOI: 10.3389/fphar.2021.628690] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]
15 Liu W, Zhang L, Xiu Z, Guo J, Wang L, Zhou Y, Jiao Y, Sun M, Cai J. Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer. Onco Targets Ther 2020;13:7229-41. [PMID: 32801752 DOI: 10.2147/OTT.S255491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]